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Lack of a Role for Cross-Reacting Anti-Thyroid
Antibodies in Chronic Idiopathic Urticaria
Jonathan D. Mozena1,2, Adrienne Tin˜ana1,2, Julie Negri1, John W. Steinke1 and Larry Borish1
The etiology of chronic idiopathic urticaria (CIU) is attributed to autoantibodies directed against the a-chain of
the high-affinity IgE receptor (FceRIa) or IgE on mast cells in 30–60% of patients. Approximately 30% of CIU
patients have Hashimoto’s thyroiditis (HT). We investigated the pathophysiologic relationship of anti-thyroid
and anti-FceRIa antibodies. Nine individuals with both CIU and HT underwent autologous serum skin testing
(ASST) and sera were assayed for thyroid autoantibodies, thyroid-stimulating hormone, and anti-FceRIa
antibodies. Serum samples were studied for their ability to activate a human mast cell line (LUVA) as determined
by cysteinyl leukotriene (CysLT) production. Experiments were performed to determine whether epitope cross-
reactivity could explain the high incidence of HT found in CIU patients. A significant proportion of CIU patients
had a positive ASST (nine of six) and anti-FceRIa antibodies (six of nine). Incubation of patient sera with FceRIa,
but not thyroglobulin or thyroid peroxidase, resulted in the decreased ability to detect anti-FceRIa antibodies.
Incubation with thyroid antigens did not inhibit CysLT production by mast cells. Epitopic cross-reactivity does
not explain the increased prevalence of HT found in CIU patients. The frequent concurrence of HT and CIU
likely reflects a genetic tendency toward autoimmune diseases.
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INTRODUCTION
Chronic idiopathic urticaria (CIU) is defined as recurrent
episodes of hives with erythema and pruritus occurring over
a period of 6 weeks or longer (Sabroe et al., 1999). CIU is a
common disorder with a prevalence of 0.1% in the general
population (Charlesworth, 2002). In the 1980s, Grattan et al.
(1986) reported the presence of a serum factor that induced
a wheal and flare response following intradermal injection
of autologous serum , thought to be reflective of the presence
of autoantibodies that are capable of inducing mast cell
(and basophil) degranulation. The autologous serum skin test
(ASST) has since been regarded as a reliable in vivo test in
predicting autoimmunity in CIU patients (Sabroe et al., 1999).
Studies have demonstrated that 30–60% of CIU patients
possess IgG autoantibodies directed against the a-subunit of the
high-affinity IgE receptor (FceRIa) on mast cells and basophils
(Hide et al., 1993; Fiebiger et al., 1995; Ferrer et al., 1998). An
additional 5–10% of CIU patients reportedly possess autoanti-
bodies directed against IgE (Gruber et al., 1988). Previous studies
have demonstrated that IgG from patients with CIU stimulates
histamine release from donor basophils in vitro suggesting a
pathogenic role for autoantibodies (Grattan et al., 1991).
Basophil activation tests have been considered the ‘‘benchmark’’
diagnostic test to identify autoimmunity as the cause of hives in
patients with CIU (Yasnowsky et al., 2006; Greaves and Tan,
2007; Altrich et al., 2009). However, the main limitation to this
approach is the inherent variability of basophils, which requires
rigorous screening of basophils from numerous donors both
to identify ‘‘releaser’’ basophils capable of FceRI-dependent
activation (Lichtenstein and MacGlashan, 1986) and also to
ensure that donor basophils do not spontaneously secrete high
basal levels of histamine. In addition, although basophils in vitro
provide useful diagnostic information, CIU is primarily a disease
of cutaneous mast cells. As basophils are not the primary cellular
target of CIU, a mast cell model is the more ideal framework to
study CIU pathophysiology.
We have developed an immortalized human mast cell line
(LUVA) displaying high concentrations of FceRI (Steinke et al.,
2009). These cells are useful in the study of immune mechanisms
of mast cell-dependant disorders such as CIU, insofar as they
degranulate and release arachidonic acid-metabolites in an
FceRI-dependant manner. The LUVA cells are activated when
incubated with CIU serum, and this activation correlates with
the presence of a positive ASST (Tin˜ana A, Mozena J, Steinke J
Screening for autoimmune mechanisms in chronic idiopathic
urticaria (CIU) utilizing an immortalized human mast cell line
(LUVA), abstract submitted to the American Academy of Allergy,
Asthma and Immunology annual meeting, February 2010).
Thyroid autoantibodies (TA) have a prevalence of
B3–6% in the general population versus B15–30% in CIU
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patients (Leznoff and Sussman, 1989; Turktas et al., 1997;
Verneuil et al., 2004; Palma-Carlos and Palma-Carlos, 2005;
Cebeci et al., 2006). Although these studies establish the
coincidental occurrence of TA and CIU, no current data exist
to determine the basis for this linkage. The confluence of
these two diseases could reflect an underlying genetic
predisposition for the development of autoimmune illnesses.
Alternatively, however, it is plausible that these diseases
are pathogenically linked, possibly reflecting a shared
epitope targeted by these different autoantibodies. Elucida-
tion of the role that TA have in CIU may ultimately help in
understanding the pathologic basis of this condition.
We initiated the current studies to further study the
relationship between the presence of anti-FceRIa antibodies
and TA in patients with CIU. Specifically, we investigated
whether the high incidence of Hashimoto’s thyroiditis (HT),
defined as the presence of antibodies to thyroglobulin (TG)
and/or thyroid peroxidase (TPO), observed in patients with
CIU could be explained by epitope cross-reactivity of anti-
FceRIa antibodies with thyroid antigens.
RESULTS
Study population
Twenty patients with CIU were enrolled in the study. The
characteristics of patients enrolled into the study are
presented in Table 1 and summarized in Table 2. The
majority of patients with CIU and HT were females
(17 females/3 males), with an average age of 38±13 years.
ASST and anti-FceRIa antibodies
Thirteen of 20 subjects had a positive ASST. In addition, 12
of 20 patients had positive anti-FceRIa antibodies. Nine of
20 patients had both a positive ASST and anti-FceRIa anti-
bodies (Tables 1 and 2).
Thyroiditis prevalence
Nine of 20 subjects were selected for further study based on
screening for the presence of either anti-TG or anti-TPO
antibodies. Six of nine of these study patients required thyroid
replacement therapy, the remainder had euthyroid HT (Table 1).
Epitope sharing between FceRIa and thyroid proteins
Initially, a CIU patient who possessed anti-FceRIa, anti-TPO, and
anti-TG antibodies was evaluated for cross-reactivity regarding
epitope binding. The ability to detect serum anti-FceRIa
antibodies was inhibited in a dose-dependent manner with
preincubation of the serum sample with increasing concentra-
tions of soluble FceRIa. However, neither recombinant TPO nor
purified TG competed with binding to FceRIa (Figure 1).
Subsequently, four additional subjects with anti-FceRIa,
anti-TPO, and anti-TG antibodies were studied for epitope
binding cross-reactivity using high concentrations of FceRIa,
TPO, and TG. The detection of anti-FceRIa antibodies by
ELISA was inhibited by an average of 93±11% when these
patient sera were incubated with human recombinant
FceRIa (Table 3). However, the ability to detect anti-FceRIa
antibodies was not inhibited when sera from the same
patients were incubated with TPO or TG (Table 3).
Functional epitope cross-reactivity
As previously reported, serum obtained from CIU patients
induced mast cell activation as demonstrated as cysteinyl
leukotriene (CysLT) secretion (Tin˜ana et al., 2009). However,
in CIU patients who possessed anti-FceRIa, anti-TPO, and
anti-TG antibodies, CysLT secretion by mast cells was not
affected by preincubation with TPO or TG (Figure 2).
Functional antibody-mediated mast cell activation
As expected, incubation with anti-FceRIa induced significant
CysLT production. In contrast to TPO and TG, this effect was
inhibited by preincubation with recombinant FceRIa (490%
inhibition) (data not shown). However, incubation with either
anti-TG or anti-TPO induced mast cell activation. In addition,
incubation with TPO and TG did not interfere with activation
of mast cells with anti-FceRIa (Figure 2).
DISCUSSION
Consistent with many other autoimmune diseases and similar
to what other investigators have reported (O’Donnell et al.,
2005; Kulthanan et al., 2006), we found that CIU typically
affects females in the third or fourth decade of life (Table 1).
In support of an autoimmune etiology to CIU, an increased
prevalence of HT in patients with CIU is well recognized with
a reported range of B15–30% (Leznoff and Sussman, 1989;
Turktas et al., 1997; Verneuil et al., 2004; Palma-Carlos and
Palma-Carlos, 2005; Cebeci et al., 2006). In contrast, the
prevalence of TA in healthy control populations is reported to
be 3.3–5.5%. In our CIU population (Table 1), a slightly
higher prevalence of TA was noted (45%).
We confirmed the use of the ASST in demonstrating the
presence of mast cell-activating function in the serum of CIU
patients (Hide et al., 1993; Toubi et al., 2004; Yasnowsky
et al., 2006). However, a positive ASST was equally prevalent
in patients who did not have TA (67 vs 64%). We also
confirmed a high prevalence of anti-FceRIa antibodies in the
serum of CIU patients as detected by ELISA (60%). However,
similar to the ASST results, an equivalent proportion of CIU
patients with and without TA had positive anti-FceRIa
antibodies (67 vs 55%, respectively). Therefore, the presence
of TA does not predict the presence of an autoimmune
‘‘signature,’’ specifically the presence of a positive ASST or
anti-FceRIa antibodies. The possibility that a larger sample
size could detect a CIU/HT autoantibody profile that
correlated with the presence of anti-FceRIa antibodies cannot
be discounted.
The mechanism by which HT is linked to CIU has not
been elucidated. Concha et al. (2004) demonstrated that 2 of
20 patients with CIU and HT possessed measurable IgE anti-
thyroid antibodies, although this has not been confirmed
(Tedeschi et al., 2001). We addressed the possibility that
epitope binding cross-reactivity could explain the concomi-
tant occurrence of these two autoimmune conditions.
However, this was comprehensively ruled out. Neither anti-
TG nor anti-TPO antibodies are capable of inducing
activation of connective tissue mast cells (Figure 2). In our
patients with CIU who possessed anti-FceRIa, TPO, and TG
antibodies, the detection of anti-FceRIa antibodies by ELISA
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was not inhibited by the addition of TG or TPO (Figure 1 and
Table 3). Finally, when we investigated functional antibody
cross-reactivity, we demonstrated that preincubation with
these thyroid proteins did not decrease the capability of CIU
serum to activate mast cells (Figure 2).
It should be noted that our diagnostic assays for the
presence of anti-FceRIa antibodies might exaggerate their
frequency. The recombinant FceRIawe used was produced in
a baculovirus cell line that has the machinery to decorate
proteins with N-linked glycans thought to have a role in
protein folding. Many humans possess pre-existing antibodies
to this host cell line-specific glycosylation motif (Hancock
et al., 2007). As such, some of the CIU patients in whom we
report anti-FceRIa antibodies may, in fact, only have
antibodies to this glycosylation motif. However, our studies
(Figure 1) do demonstrate that this glycosylation motif does
not interfere with the ability of soluble recombinant FceRIa to
capture IgE receptor-targeted antibodies. This latter observa-
tion validates our reporting the absence of cross-reacting
functional antibodies.
In summary, our data confirm the high prevalence of
TA and anti-FceRIa antibodies in CIU. However, this pheno-
menon cannot be explained by the presence of a shared
epitope recognized by these two different antibodies.
Table 1. Characteristics of CIU population
Patient Sex Age Thyroid replacement Anti-TPO antibodies Anti-TG antibodies ASST1 Anti-FceRIa antibodies2
Thyroiditis cohort
1 F 56 No No Yes Negative Positive
2 F 28 No No Yes Positive Positive
3 F 45 Yes Yes No Positive Positive
4 M 65 Yes No Yes Positive Positive
5 F 40 Yes Yes Yes Positive Positive
6 F 29 Yes Yes Yes Negative Negative
7 F 61 Yes Yes Yes Negative Negative
8 F 21 Yes Yes Yes Positive Negative
9 F 24 No No Yes Positive Positive
Non-thyroiditis cohort
10 F 32 — — — Positive Negative
11 F 35 — — — Positive Positive
12 F 61 — — — Positive Positive
13 M 29 — — — Negative Negative
14 F 27 — — — Positive Positive
15 M 47 — — — Negative Positive
16 F 46 — — — Positive Negative
17 F 27 — — — Positive Positive
18 F 37 — — — Negative Negative
19 F 33 — — — Negative Positive
20 F 25 — — — Positive Negative
Abbreviations: ASST, autologous serum skin testing; CIU, chronic idiopathic urticaria; F, female; FceRIa, a-chain of the high-affinity IgE receptor; M, male;
TG, thyroglobulin; TPO, thyroid peroxidase.
1Positive ASST defined as wheal 45mm in diameter more than saline controls.
2Positive anti-FceRIa titer defined as 43.9 mgml1.
Table 2. Summary of characteristics of CIU population
Sex (# female) Age (mean years±SD) ASST (# positive) Anti-FceRIa antibodies (# positive)
Thyroiditis cohort (n=9) 8/9 41±16 6/9 6/9
Non-thyroiditis cohort (n=11) 9/11 36±10 7/11 6/11
Abbreviations: ASST, autologous serum skin testing; CIU, chronic idiopathic urticaria; FceRIa, a-chain of the high-affinity IgE receptor.
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An alternative explanation for the increased incidence of HT
in CIU is that these conditions reflect a shared genetic pre-
disposition toward the development of autoimmune disease.
Along the same lines, autoimmune thyroid disease also has
a tendency to occur concurrently with type 1 diabetes. This
co-association has frequently been found to occur with
patients who express HLA-DR3, suggesting that their etiology
may involve common genetic factors (Levin et al., 2004). This
possibly reflects shared thymic-programmed mechanisms for
developing self-tolerance. In summary, our data confirm the
high prevalence of TA and anti-FceRIa antibodies in CIU and
strongly suggests that anti-thyroid and anti-FceRIa antibodies
do not share epitope specificity.
MATERIALS AND METHODS
Patient enrollment
Patients with CIU were recruited from the outpatient adult allergy/
immunology clinics at the University of Virginia. Subjects gave
written informed consent under a protocol approved by the
University of Virginia human institutional review board. The study
was carried out in accordance with the Declaration of Helsinki
principles. Subjects were diagnosed with CIU based on the presence
of urticarial lesions of 46 weeks duration who had hives present
at least 3 days per week. All patients had their blood screened
for thyroid-stimulating hormone, free T4 (if thyroid-stimulating
hormone abnormal), anti-TPO antibody, and anti-TG antibody.
Patients with significant elevation in circulating antibodies to either
TPO (40.7 IUml1) or TG (40.6 IUml1) were defined as having
HT and invited to participate in further studies. Patients with a
history of autoimmune disease (other than HT), chronic infection, or
malignancy were excluded. Antihistamines were discontinued for
a minimum of 5 days before skin testing. Patients on immuno-
suppressive medications (for example cyclosporine, plaquenil) were
excluded, as were patients who had used corticosteroids within the
previous 2 months.
Anti-FceRIa antibody assay
Phosphate-buffered saline (PBS) with or without 200 ng l1 of
recombinant human FceRIa (Heska, Fort Collins, CO) were incu-
bated overnight and adsorbed onto sterile flat-bottomed Immulon
2HB 96-well ELISA plates (Beckman Coulter, Fullerton, CA). The
concentration of 200 ng l1 FceRIa was determined experimentally
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Figure 1. Inhibition assay using recombinant FceRIa, TPO, and
thyroglobulin. Serum from one patient who had anti-FceRIa and TA was
diluted 1:50 in PBS containing 0.05% sodium azide and incubated overnight
at 37 1C with increasing concentrations of recombinant human FceRIa,
purified human TG, or recombinant human TPO. Titers of anti-FceRIa
antibodies were measured using the methodology described.
Table 3. Anti-FceRIa inhibition assay with FceRIa, thyroid peroxidase, and thyroglobulin
Serum incubated with
recombinant FceRIa
Serum incubated with purified
thyroglobulin
Serum incubated with recombinant
thyroid peroxidase
% Inhibition of anti-FceRIa antibody
detection (±SD)
93±11* 17±16 8±12
FceRIa, a-chain of the high-affinity IgE receptor.
*Po0.05.
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Figure 2. Anti-FceRIa functional assay. Comparison of CysLT production
after: (a) activation with PBS, anti-thyroglobulin, and anti-TPO antibodies;
(b) preincubation with thyroid antigens followed by activation with
anti-FceRIa; and (c) preincubation with thyroid antigens followed by
activation with patient serum. (a ) LUVA mast cells were activated with PBS,
anti-TG, or anti-TPO antibodies to evaluate if anti-thyroid antibodies caused
mast cell activation. (b) Additional mast cells were preincubated with
recombinant TPO or purified TG followed by activation with anti-Fc eRIa to
determine if thyroid antigens interfere with activation of cells. (c) Sera from
patients with positive anti-TG (n ¼ 8) or anti-TPO (n ¼ 5) antibodies were
diluted 1:20 and incubated with thyroid antigens overnight. This was followed
by activation of LUVA mast cells to determine if preincubation with the
thyroid antigens inhibited CysLT production. For all experiments, activation
took place over 30minutes at 37 1 C. Supernatants were collected and
CysLT production quantified by ELISA as described. Results presented in
panels a and b were from a single experiment with the LUVA cells and thus
have no error bars, whereas in panel c the error bars represent the standard
error of the mean.
www.jidonline.org 1863
JD Mozena et al.
Thyroid Autoimmunity and CIU
and found to yield comparable results to higher concentrations.
The next day, wells were washed and blocked with 10% goat serum
in PBS (pH 7.4; Sigma, St Louis, MO) for 4 hours. After washing,
plates were incubated with 100 ml human sera in duplicate diluted
1:100 in PBS containing 5% goat serum at 4 1C for 1 hour. Plates
were rinsed before adding biotinylated anti-human IgG 1:10,000
(Rockland Immunochemicals, Gilbertsville, PA) in 5% goat serum
and incubated for 1 hour at 4 1C. After washing, 100 ml of horseradish
peroxidase-conjugated streptavidin (Sigma) diluted 1:10,000 in PBS
was incubated in wells for 20minutes. The ELISA was developed
with o-phenylenediamine dihydrochloride 0.4mgml1 (Sigma) in
0.05% phosphate-citrate buffer with sodium perborate (Sigma) for
B20minutes before the reaction was terminated with 3N sulfuric
acid (after the optical density of the most concentrated portion of the
standard curve was between 1.5 and 2.0 (see below)). Measured
values were translated into antibody concentrations by logarithmic
regression analysis using standardized human IgG (Sigma) directly
adsorbed to the plate (comprising a linear range from 0 to
1,000ngml1). On the basis of preliminary testing performed in a
large cohort of CIU patients (data not shown), a positive anti-FceRIa
assay was defined as a concentration of 43.9 mgml1.
Autologous serum skin test
ASST was performed using standard methodology (Sabroe et al.,
1999). Blood was drawn into a glass tube, allowed to clot, and
centrifuged at 5,000 r.p.m. for 15minutes to separate sera. Patient
sera (50 ml) was injected intradermally into the ventral forearm and
compared with saline and histamine controls. Skin tests were read
after 30minutes with wheals measuring 45mm in diameter more
than saline defined as positive.
Anti-FceRIa inhibition binding assay
Inhibition assays were performed to determine whether a shared
epitope recognized by both anti-FceRIa and TA could explain the
high incidence of HT associated with CIU. Initially one serum
sample from a subject who possessed anti-FceRIa, anti-TG, and anti-
TPO antibodies was diluted 1:50 in PBS and incubated overnight at
37 1C with either PBS, recombinant human FceRIa, human TG
(Advanced Immunochemicals, Long Beach, CA), or recombinant
human TPO (Research Diagnostics, Flanders, NJ) at a range of
concentrations and then assayed for the presence of anti-FceRIa
antibodies by ELISA as described. An experiment was then
performed with four representative patients who also had all three
classes of autoantibodies with high concentrations of recombinant
human FceRIa, TG, or TPO (at 65 mgml1 each).
Anti-FceRIa inhibition functional assay
Serum was diluted 1:20 in PBS and incubated with PBS,
recombinant TPO, or purified TG (65 mgml1 each) overnight as
described for the binding assay. The next day, the serum samples
were incubated with LUVA mast cells at 37 1C for 30minutes and
supernatants collected. LUVA activation was determined as CysLT
secretion as quantified by ELISA according to the manufacturer’s
instructions (Cayman Chemical, Ann Arbor, MI).
Anti-FceRIa functional assay
LUVA mast cells were incubated with PBS, and commercially
available anti-TG (Sigma) and anti-TPO (Biodesign International,
Saco, ME) antibodies for 30minutes at 37 1C and supernatants were
collected. Similarly, LUVA mast cells were incubated with
recombinant anti-FceRIa (Upstate, Lake Placid, NY) alone and
anti-FceRIa after preincubating with recombinant soluble FceRIa
(Heska) for 15minutes. In addition, LUVA mast cells were
preincubated with recombinant TPO and purified TG for 15minutes
followed by incubation with anti-FceRIa for 15minutes. LUVA
activation was determined as CysLT secretion as described above.
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